Evidence map›Paper›PMID 38129830›Full record

Observational studyBMC public health2023

A population-based study of the trend in SARS-CoV-2 diagnostic modalities from the beginning of the pandemic to the Omicron surge in Kyoto City, Kyoto, Japan.

Hiroki Kyo, Shivani A Patel, Masaki Yamamoto, Yasufumi Matsumura, Takeshi Ikeda, Miki Nagao

Abstract readObservational Study
In one paragraph

Observational study in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hiroki KyoMetroAtlanta Ambulance Service, Emory Healthcare Network, Atlanta, GA, USA.
Shivani A PatelHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Masaki YamamotoDepartment of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yasufumi MatsumuraDepartment of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takeshi IkedaPublic Health and Welfare Bureau of Kyoto City, Kyoto, Japan.
Miki NagaoDepartment of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. mnagao@kuhp.kyoto-u.ac.jp.

Funding

Japan Science and Technology Agency JPMJSC2107
6 · The paper itself

Abstract

backgroundThe coronavirus disease 2019 (COVID-19) presents critical diagnostic challenges for managing the pandemic. We investigated the 30-month changes in COVID-19 testing modalities and functional testing sites from the early period of the pandemic to the most recent Omicron surge in 2022 in Kyoto City, Japan.

methodsThis is a retrospective-observational study using a local anonymized population database that included patients' demographic and clinical information, testing methods and facilities from January 2020 to June 2022, a total of 30 months. We computed the distribution of symptomatic presentation, testing methods, and testing facilities among cases. Differences over time were tested using chi-square tests of independence.

resultsDuring the study period, 133,115 confirmed COVID-19 cases were reported, of which 90.9% were symptomatic. Although nucleic acid amplification testing occupied 68.9% of all testing, the ratio of lateral flow devices (LFDs) rapidly increased in 2022. As the pandemic continued, the testing capability was shifted from COVID-19 designated facilities to general practitioners, who became the leading testing providers (57.3% of 99,945 tests in 2022).

conclusionsThere was a dynamic shift in testing modality during the first 30 months of the pandemic in Kyoto City. General practitioners increased their role substantially as the use of LFDs spread dramatically in 2022. By comprehending and documenting the evolution of testing methods and testing locations, it is anticipated that this will contribute to the establishment of an even more efficient testing infrastructure for the next pandemic.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingHumansJapanPandemicsRetrospective StudiesActive epidemiological investigationAntigen testingCOVID-19NAATSARS-CoV-2Testing modality

Identifiers

PMID38129830
PMCPMC10734122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.